182 related articles for article (PubMed ID: 3585492)
1. Technetium-99m-labeled monoclonal antibody with preserved immunoreactivity and high in vivo stability.
Arano Y; Yokoyama A; Furukawa T; Horiuchi K; Yahata T; Saji H; Sakahara H; Nakashima T; Koizumi M; Endo K
J Nucl Med; 1987 Jun; 28(6):1027-33. PubMed ID: 3585492
[TBL] [Abstract][Full Text] [Related]
2. Optimum conditions for labeling of DTPA-coupled antibodies with technetium-99m.
Childs RL; Hnatowich DJ
J Nucl Med; 1985 Mar; 26(3):293-9. PubMed ID: 3882905
[TBL] [Abstract][Full Text] [Related]
3. 99mTc labeling of proteins: initial evaluation of a novel diaminedithiol bifunctional chelating agent.
Baidoo KE; Scheffel U; Lever SZ
Cancer Res; 1990 Feb; 50(3 Suppl):799s-803s. PubMed ID: 2297727
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of a new bifunctional chelating agent for 99mTc labeling proteins: p-carboxyethylphenylglyoxal-di(N-methylthiosemicarbazone).
Arano Y; Yokoyama A; Magata Y; Saji H; Horiuchi K; Torizuka K
Int J Nucl Med Biol; 1986; 12(6):425-30. PubMed ID: 3710705
[TBL] [Abstract][Full Text] [Related]
5. Bifunctional NHS-BAT ester for antibody conjugation and stable technetium-99m labeling: conjugation chemistry, immunoreactivity and kit formulation.
Eisenhut M; Lehmann WD; Becker W; Behr T; Elser H; Strittmatter W; Steinsträsser A; Baum RP; Valerius T; Repp R; Deo Y
J Nucl Med; 1996 Feb; 37(2):362-70. PubMed ID: 8667077
[TBL] [Abstract][Full Text] [Related]
6. Bis(hydroxamamide)-based bifunctional chelating agent for 99mTc labeling of polypeptides.
Xu LC; Nakayama M; Harada K; Kuniyasu A; Nakayama H; Tomiguchi S; Kojima A; Takahashi M; Ono M; Arano Y; Saji H; Yao Z; Sakahara H; Konishi J; Imagawa Y
Bioconjug Chem; 1999; 10(1):9-17. PubMed ID: 9893958
[TBL] [Abstract][Full Text] [Related]
7. Preparation and properties of antitumor monoclonal antibodies labeled with metallic radionuclides indium-111, gallium-67, and technetium-99m.
Endo K; Sakahara H; Nakashima T; Koizumi M; Ohta H; Kawamura Y; Kunimatsu M; Furukawa T; Ohmomo Y; Arano Y
NCI Monogr; 1987; (3):135-40. PubMed ID: 3469526
[TBL] [Abstract][Full Text] [Related]
8. Technetium-99m labelling of the IOR CEA 1 monoclonal antibody: evaluation of different methods.
Gano L; Fernandes C; Cantinho G; Santos AI; Pena H; Vieira R; Salgado L; Patrício L
Nuklearmedizin; 1997 Sep; 36(6):205-12. PubMed ID: 9380538
[TBL] [Abstract][Full Text] [Related]
9. Reduction-mediated technetium-99m labeling of monoclonal antibodies.
Mather SJ; Ellison D
J Nucl Med; 1990 May; 31(5):692-7. PubMed ID: 2341907
[TBL] [Abstract][Full Text] [Related]
10. Direct labeling of monoclonal antibodies with technetium-99m by photoactivation.
Sykes TR; Woo TK; Baum RP; Qi P; Noujaim AA
J Nucl Med; 1995 Oct; 36(10):1913-22. PubMed ID: 7562064
[TBL] [Abstract][Full Text] [Related]
11. Reassessment of diethylenetriaminepentaacetic acid (DTPA) as a chelating agent for indium-111 labeling of polypeptides using a newly synthesized monoreactive DTPA derivative.
Arano Y; Uezono T; Akizawa H; Ono M; Wakisaka K; Nakayama M; Sakahara H; Konishi J; Yokoyama A
J Med Chem; 1996 Aug; 39(18):3451-60. PubMed ID: 8784442
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and dosimetry of technetium-99m-hydrazino nicotinamide IgG: comparison with indium-111-DTPA-IgG.
Callahan RJ; Barrow SA; Abrams MJ; Rubin RH; Fischman AJ
J Nucl Med; 1996 May; 37(5):843-6. PubMed ID: 8965158
[TBL] [Abstract][Full Text] [Related]
13. The effect of chelating agents on the distribution of monoclonal antibodies in mice.
Ward MC; Roberts KR; Westwood JH; Coombes RC; McCready VR
J Nucl Med; 1986 Nov; 27(11):1746-50. PubMed ID: 3464701
[TBL] [Abstract][Full Text] [Related]
14. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.
von Guggenberg E; Behe M; Behr TM; Saurer M; Seppi T; Decristoforo C
Bioconjug Chem; 2004; 15(4):864-71. PubMed ID: 15264875
[TBL] [Abstract][Full Text] [Related]
15. 99mTc-labelled compounds prepared with sodium dithionite as reducing agent.
Vilcek S; Kalincák M; Machán V
Nuklearmedizin; 1981 Dec; 20(6):283-9. PubMed ID: 6460222
[TBL] [Abstract][Full Text] [Related]
16. In the procurement of stable 99mTc labeled protein using bifunctional chelating agent.
Arano Y; Yokoyama A; Magata Y; Horiuchi K; Saji H; Torizuka K
Int J Rad Appl Instrum A; 1986; 37(7):587-92. PubMed ID: 3021660
[TBL] [Abstract][Full Text] [Related]
17. Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes.
Malviya G; D'Alessandria C; Bonanno E; Vexler V; Massari R; Trotta C; Scopinaro F; Dierckx R; Signore A
J Nucl Med; 2009 Oct; 50(10):1683-91. PubMed ID: 19759100
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics.
van Gog FB; Visser GW; Klok R; van der Schors R; Snow GB; van Dongen GA
J Nucl Med; 1996 Feb; 37(2):352-62. PubMed ID: 8667076
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
[TBL] [Abstract][Full Text] [Related]
20. Simplified preformed chelate protein radiolabeling with technetium-99m mercaptoacetamidoadipoylglycylglycine (N3S-adipate).
Kasina S; Sanderson JA; Fitzner JN; Srinivasan A; Rao TN; Hobson LJ; Reno JM; Axworthy DB; Beaumier PL; Fritzberg AR
Bioconjug Chem; 1998; 9(1):108-17. PubMed ID: 9460553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
